719_729_R

Psychiatr. Pol. 2018; 52(4): 719–729

 

Fakher Rahim, Mehdi Sayyah
 

 

FREE ENGLISH FULLTEXT: Effects of atorvastatin on treatment-resistant obsessive-compulsive disorder: A double-blind randomized trial

Summary
Objective. Obsessive-compulsive disorder (OCD) is a chronic disorder of unknown etiology. An augmentation strategy is an approach for treatment-resistant OCD. This study was planned to assess the effect of atorvastatin on treatment-resistant OCD.
Methods. This 12-week-long double-blind randomized trial was performed on 26 adult patients with treatment-resistant OCD. They were diagnosed with this kind of disorder based on the DSM-IV-TR. The patients were randomized to receive either 10 mg/day atorvastatin or placebo. The Yale-Brown scale was assessed at the baseline and 12 weeks later.
Results. There were significant reductions in the obsession subtotal scoreof the Y-BOCS (p = 0.017) and the total Y-BOCS score (p = 0.041) in the atorvastatin group. Hence, the reduction in the Y-BOCS compulsive score (p = 0.081) was not statistically significant. Atorvastatin was generally well tolerated. There was a significant reduction in libido in the atorvastatin group (p = 0.019).
Conclusions. The results of this study should be interpreted in the shadow of its restrictions. Some of the restrictions were a limited number of patients in the trial, a 12-week-long time Iranian Randomized Clinical Trial Registry Code: IRCT201511217290N2. trial, and not measuring NO before and after the study. It is recommended that researchers should consider these items in similar type of studies.

 

ISSN 0033-2674 (PRINT)

ISSN 2391-5854 (ONLINE)


Psychiatria Polska
is an Open Access journal:
Creative Commons: CC-BY
SHERPA RoMEO:
Blue


Zadanie finansowane
w ramach umowy
nr 739/P-DUN/2018
ze środków MNiSW
przeznaczonych
na działalność
upowszechniającą naukę



Inne strony PTP:
Other PTP websites:

www.psychiatria.org.pl
www.psychiatriapsychoterapia.pl

www.archivespp.pl
www.psychoterapiaptp.pl

Psychiatria Polska
INDEXED IN:
Thomson Reuters Master List
Science Citation Index Expanded
Journal Citation Reports
(Impact Factor 1,196)

Medline/Index Medicus
MNiSW (15 pkt)
Scopus/SCImago
EMBASE/Excerpta Medica
PsycINFO, EBSCO, DOAJ
Index Copernicus
Erih Plus, Cochrane Library
CrossRef/DOI

We recommend:

Pharmacological Reports

 


+48  518-330-994
kontakt z Biurem KRW PTP